Long-Term Follow-Up from CheckMate 214 in Advanced RCC

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Related Keywords

,Advanced Renal Cell Carcinoma ,Term Follow Up ,Renal Cell Carcinoma ,Nrcc ,Advanced Rcc ,Checkmate 214 ,Nivolumab ,Ipilimumab ,Metastatic Clear Cell Rcc ,Ctla4 Inhibition ,Ctla4 ,Metastatic Clear Cell Renal Carcinoma ,